Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Hyperoxaluria Type 1: early-phase trial registry
1 of 2 indexed Primary Hyperoxaluria Type 1 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Primary Hyperoxaluria Type 1: 2 US clinical trials tracked, 1 recruiting.
Primary Hyperoxaluria Type 1 is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, running 1 of these trials.
Enrollment posture brief
Registry condition primary-hyperoxaluria-type-1
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Primary Hyperoxaluria Type 1 lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Hyperoxaluria Type 1 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Hyperoxaluria Type 1 is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
NCT04580420
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
Alnylam Pharmaceuticals
NCT04982393
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Hyperoxaluria Type 1 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Hyperoxaluria Type 1 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Hyperoxaluria Type 1 page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Primary Hyperoxaluria Type 1 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company sponsors the most Primary Hyperoxaluria Type 1 trials on record, review their full trial history before evaluating a specific study. See Dicerna Pharmaceuticals, Inc., a Novo Nordisk company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Hyperoxaluria Type 1 condition card totals 2 registered trials; most-linked intervention DCR-PHXC; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.